Feed Preview

Fast Growing

Incretin & Type 1 Diabetes

StudioMolekuul, Shutterstock

Incretins are metabolic hormones that stimulate a decrease in glucose levels in the blood and they have been implicated in glycemic regulation in the remission phase of type 1 diabetes. Here is the latest research.

Top 20 most recent papers

Update on the Impact, Diagnosis and Management of Cardiovascular Autonomic Neuropathy in Diabetes: What Is Defined, What Is New, and What Is Unmet

Diabetes & Metabolism JournalFebruary 23, 2019

Vincenza Spallone

How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials

Arteriosclerosis, Thrombosis, and Vascular BiologyJanuary 31, 2020

Matthew M Y LeeNaveed Sattar

Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?

Trends in Endocrinology and Metabolism : TEMDecember 12, 2019

Jennifer R SnaithJerry R Greenfield

Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases

Pharmacoepidemiology and Drug SafetyAugust 29, 2019

Lu WangNorman Rosenthal

Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes

International Journal of Molecular SciencesNovember 24, 2019

Vjera NinčevićInes Bilić Ćurčić

Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial

The Lancet. Diabetes & EndocrinologyMarch 6, 2020

Nicklas J JohansenFilip Krag Knop

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives

Cardiovascular DiabetologyMarch 2, 2019

Chiara Maria Assunta CefaloAndrea Giaccari

Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy

British Journal of Clinical PharmacologyJuly 25, 2019

Christina BrockBirgitte Brock

GLP-1 receptor agonists in type 1 diabetes: a MAG1C bullet?

The Lancet. Diabetes & EndocrinologyMarch 6, 2020

Michael A Nauck, Juris J Meier

Renal effects of glucagon-like peptide receptor agonists in patients with type 1 diabetes mellitus

Terapevticheskiĭ arkhivFebruary 1, 2019

O K VikulovaI I Dedov

Therapeutic Experience of Saxagliptin as First Add-on after Metformin in Indian Type 2 Diabetes Patients: A Non-interventional, Prospective, Observational Study (ONTARGET-INDIA)

Indian Journal of Endocrinology and MetabolismOctober 24, 2019

Sanjay KalraAmit Kumar

Pharmacologic treatment options for type 1 diabetes: what's new?

Expert Review of Clinical PharmacologyMarch 21, 2019

Laura M NallyWilliam Tamborlane

Using DPP-4 inhibitors to modulate beta cell function in type 1 diabetes and in the treatment of diabetic kidney disease

Expert Opinion on Investigational DrugsMarch 9, 2019

Hugh DavisStephen N Davis

Liraglutide Exerts Potential Anti-inflammatory Effect in Type 1 Diabetes by Inhibiting IFN-γ Production via Suppressing JAK-STAT Pathway

Endocrine, Metabolic & Immune Disorders Drug TargetsMarch 5, 2019

Yunjuan ZhaoWangen Li

Serum adipocytokines are associated with microalbuminuria in patients with type 1 diabetes and incipient chronic complications

Diabetes & Metabolic SyndromeJanuary 16, 2019

Tomislav BulumLea Duvnjak

The dipeptidyl peptidase 4 inhibitor sitagliptin improves oxidative stress and ameliorates glomerular lesions in a rat model of type 1 diabetes

Life SciencesAugust 10, 2019

Catarina MarquesRosa Fernandes

Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man

Frontiers in EndocrinologyNovember 30, 2019

James E Foley

Improving Effects of Peptides on Brain Malfunction and Intranasal Delivery of Those Derivatives to the Brain

Yakugaku zasshi : Journal of the Pharmaceutical Society of JapanMay 8, 2019

Jun-Ichiro Oka

The journey from gene knockout to clinical medicine: telotristat and sotagliflozin

Drug Design, Development and TherapyMarch 19, 2019

Marc S Rendell

The neuroprotection of liraglutide on diabetic cognitive deficits is associated with improved hippocampal synapses and inhibited neuronal apoptosis

Life SciencesJune 16, 2019

Wenhui YanLina Chen

See more papers from this feed

Related Feeds

Acute Disseminated Encephalomyelitis

Acute disseminated encephalomyelitis (ADEM) is a rare inflammatory demyelinating disease of the central nervous system. Discover the latest research on acute disseminated encephalomyelitis here.

Addison Disease

Addison's disease, also known as primary adrenal insufficiency and hypocortisolism, is a long-term endocrine disorder in which the adrenal glands do not produce enough steroid hormones. Discover the latest research on Addison's disease here.

Adult-Onset Still's Disease

Adult-onset Still's disease (AOSD) is a form of Still's disease, a rare systemic autoinflammatory disease characterized by the classic triad of persistent high spiking fevers, joint pain, and a distinctive salmon-colored bumpy rash. Discover the latest research on AOSD here.

Aging & Diabetes

This feed focuses on the role of the aging process on developing diabetes.

Anti-N-Methyl-D-Aspartate Receptor Encephalitis

Anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis is a form of of brain inflammation due to antibodies against NMDA receptors. Discover the latest research on anti-NMDA receptor encephalitis here.

Antidiabetic Cellular Plasticity

This feed focuses on mechanisms that underlie cellular plasticity as a treatment for diabetes and other degenerative diseases.

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Asprosin

Asprosin is a fasting-induced hormone produced in the white adipose tissue to stimulate the hepatic release of glucose into the bloodstream. Discover the latest research on this protein hormone here.

Contact Help Terms Privacy Cookies